Han Biomedical (ROCO:6999) EBITDA Margin %: 31.58% (As of Dec. 2025) — 23% Below Median


ROCO:6999 Han Biomedical Inc ROCO:6999
25 GF Score
Price NT$30.00
! 1 Warning Sign
View Full Analysis

What is Han Biomedical EBITDA Margin %?

Han Biomedical ROCO:6999 +0.17% 25 EBITDA Margin % is 31.58% as of Dec. 2025, which is 23% below its 10-year median of 41.18. GuruFocus rates ROCO:6999 with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 936 Biotechnology companies, Han Biomedical ranks better than 88.57% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Han Biomedical's EBITDA for the six months ended in Dec. 2025 was NT$20.7 Mil. Han Biomedical's Revenue for the six months ended in Dec. 2025 was NT$65.4 Mil. Therefore, Han Biomedical's EBITDA margin for the quarter that ended in Dec. 2025 was 31.58%.

Han Biomedical  (ROCO:6999) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Han Biomedical EBITDA Margin % Related Terms

Han Biomedical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Han Biomedical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Han Biomedical EBITDA Margin % Chart

Han Biomedical Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
41.86 43.16 41.18 36.54 30.08

Han Biomedical Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial 43.61 36.98 36.18 28.47 31.58

ROCO:6999 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Han Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Han Biomedical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Han Biomedical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Han Biomedical's EBITDA Margin % falls into.


ROCO:6999
25GF Score
Han Biomedical Inc ROCO:6999
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Han Biomedical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Han Biomedical's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=37.965/126.209
=30.08 %

Han Biomedical's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=20.651/65.393
=31.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 31.58% mean?
Han Biomedical (ROCO:6999) has a EBITDA Margin % of 31.58% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Han Biomedical and its competitors. This is 23% below median its historical median of 41.18. Over the past decade, Han Biomedical's EBITDA Margin % has ranged from 30.08 to 43.16. According to the industry distribution chart, Han Biomedical ranks #107 out of 936 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Han Biomedical's EBITDA Margin % too high?
Han Biomedical's current EBITDA Margin % of 31.58% is 23% below median its 10-year median of 41.18. Over the past 10 years, this metric has ranged from a low of 30.08 to a high of 43.16. Based on the distribution chart, Han Biomedical ranks #107 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Han Biomedical has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Han Biomedical's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Han Biomedical ranks #107 out of 936 companies for EBITDA Margin %. This places Han Biomedical in the top 11% of its industry — outperforming the majority of peers. Historically, Han Biomedical's own EBITDA Margin % has ranged from 30.08 to 43.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Han Biomedical and its competitors. Han Biomedical's current EBITDA Margin % is 31.58%, which is 23% below median its own 10-year median of 41.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Han Biomedical stock overvalued right now?
Han Biomedical (ROCO:6999) has a current EBITDA Margin % of 31.58%. The current EBITDA Margin % is 31.58%, which is 23% below median its 10-year median of 41.18. Han Biomedical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Han Biomedical (ROCO:6999), the current EBITDA Margin % is 31.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Han Biomedical Business Description

Address Xintai 5th Road, 15F-11, No.99, Sec.1, Xizhi District, New Taipei City, TWN
Han Biomedical Inc operates as a bio-material technology platform for the tissue repair market.
25GF Score

Get the complete analysis for ROCO:6999

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.00
Price